AstraZeneca stock slips in after-hours trading on EU opinion news
Published on 09/21/2026 at 22:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock ended the U.S. session without a substantiated NYSE close in the search results, so the session can only be summarized with the latest dated market move. Reuters said the drugmaker's cancer treatment Enhertu was recommended for EU approval, and the shares slipped 0.8 percent in Europe.
September 21, 2026 session and catalyst
AstraZeneca PLC (ISIN GB0009895292) moved on two European regulatory updates on September 21, 2026. Reuters reported that AstraZeneca's Enhertu was recommended for EU approval for use in early breast cancer, while another Reuters-linked report noted a separate EU panel nod for Klygefa. The U.S.-listed ADR comparison could not be substantiated here, so the move is best read against the 0.8 percent decline reported in Europe.
After the bell and next session
StockTitan carried an AstraZeneca 6-K current report on September 21, 2026, and Reuters-linked coverage on the same day pointed to the EU panel recommendations as the main catalyst. The next U.S. trading session is September 22, 2026, and any follow-through should be read alongside that regulatory news and the company filing.
On Xetra, the shares were down 0.40 percent at 9:15 a.m. ET and later down 0.4 percent at 9:28 a.m. ET, showing the European session was weaker before the U.S. close.
